An early-phase study with R/R FLT3 mutated AML patients [58] [50% exposed to prior FLT3 inhibitors] showed a sustained CRi/CRp (complete remission with incomplete hematological recovery/complete remission with incomplete platelet recovery) in 29% (4/14), and two additional patients (14%) showed more than 50% blast reduction. This evidence concerns the gene FLT3 and acute myeloid leukemia.